Trial Profile

A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd on the progression to type 1 diabetes in children with multiple islet cell autoantibodies

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2024 According to a Diamyd Medical AB media release, the data of this trial will be presented at the 50th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Lisbon, Portugal, on October 16-19, 2024, and the 21st Immunology of Diabetes Society (IDS) Congress in Bruges, Belgium, on November 4-8, 2024.
26 Oct 2023 According to a Diamyd Medical AB media release, results were presented in 2017 in Pediatric Diabetes.
30 May 2022 According to a Diamyd Medical AB media release, data from this trial have been published in the scientific journal Journal of Immunology Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com